Feline Immunodeficiency Virus : Current Knowledge and Future Directions

Research output: Journal Publications and ReviewsRGC 21 - Publication in refereed journalpeer-review

View graph of relations

Detail(s)

Original languageEnglish
Pages (from-to)145-159
Number of pages15
Journal / PublicationAdvances in Small Animal Care
Volume3
Issue number1
Online published31 Oct 2022
Publication statusPublished - Nov 2022

Link(s)

Abstract

• Clinical outcomes in FIV-infected cats are variable and poorly defined. The immunodeficiency that accompanies infection can, and often does, remain subclinical.

• FIV infection is lifelong. Serology is the first-line diagnostic test to identify infected cats. PCR is available for confirmation if required.

• Viral, host, and environmental factors that influence prognosis in individual FIV-infected cats are unclear. Reliable surrogate markers to predict clinical progression are not available.

• Key to the management of FIV-infected cats is preventive health care and early detection and investigation of clinical problems.

• A commercial FIV vaccine is available in only a few regions including Australia, New Zealand, and Japan. Interference with diagnostic testing by the commercial FIV vaccine is largely resolved, but vaccine efficacy in the field remains questionable. FIV vaccination is classified as noncore by WSAVA Vaccination Guidelines Group.

Research Area(s)

  • Retrovirus, Lentivirus, Immunodeficiency, Viral diversity, Receptor usage, CD134, CXCR4, Vaccine

Download Statistics

No data available